The prasugrel new drug application (NDA) is still under discussion with the US FDA

Author：  

Publisher： Adis International

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1661, 2008-01, pp. : 19-19

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Astellas Pharma's Supplemental New Drug Application (sNDA) for injectable micafungin [Mycamine] has been approved by the US FDA.

By  

Inpharma, Vol. 1, Iss. 1623, 2008-01 ,pp. : 18-18

Adis International

Access to resources Recommend Favorite

Treprostinil NDA accepted for review by US FDA.

By  

Inpharma, Vol. 1, Iss. 1655, 2008-01 ,pp. : 19-19

Adis International

Access to resources Recommend Favorite

US FDA reports new steps in drug safety

By  

Inpharma, Vol. 1, Iss. 1574, 2007-01 ,pp. : 21-21

Adis International

Access to resources Recommend Favorite

The US FDA requires a "new vision of drug safety"

By  

Inpharma, Vol. 1, Iss. 1561, 2006-01 ,pp. : 2-2

Adis International

Access to resources Recommend Favorite

Endo Pharmaceuticals received a "not approvable" letter from the US FDA regarding their supplemental New Drug Application for frovatriptan [Frova]

By  

Inpharma, Vol. 1, Iss. 1609, 2007-01 ,pp. : 23-23

Adis International

Access to resources Recommend Favorite